Role of Riluzole in Amyotrophic Lateral Sclerosis
نویسندگان
چکیده
منابع مشابه
Op-brai130085 1361..1370
Riluzole, a benzothiazole derivative, has been shown to be effective in prolonging survival in amyotrophic lateral sclerosis. The mechanisms by which riluzole exerts neuroprotective effects in amyotrophic lateral sclerosis remains to be fully elucidated, although inhibition of glutamatergic transmission and modulation of Na + channel function have been proposed. In an attempt to determine the m...
متن کاملThe Role of the Statistical Method of Motor Unit Number Estimation (MUNE) to Assess the Potential Therapeutic Benefits of Riluzole on Patients with Pre-symptomatic Familial Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which attacks the motor system. There is a family history in approximately 10% percent of cases and 20% of such families have point mutations in the Cu, Zn superoxide dimutase 1 (SOD1) gene. Pre-symp‐ tomatic loss of motor neurons has been identified prior to the onset of symptoms in SOD1 mice. This loss was biphasic with ...
متن کاملPartial Block by Riluzole of Muscle Sodium Channels in Myotubes from Amyotrophic Lateral Sclerosis Patients
Denervated muscles undergo fibrillations due to spontaneous activation of voltage-gated sodium (Na(+)) channels generating action potentials. Fibrillations also occur in patients with amyotrophic lateral sclerosis (ALS). Riluzole, the only approved drug for ALS treatment, blocks voltage-gated Na(+) channels, but its effects on muscle Na(+) channels and fibrillations are yet poorly characterized...
متن کاملPotential Therapeutic Benefits of Riluzole in Pre-Symptomatic Familial Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which attacks the motor system. Current treatment for sporadic ALS or Cu, Zn superoxide dimutase 1 (SOD 1 mutation) familial ALS, produces only a modest increase in survival. Riluzole, has been available since 1995 and remains the only disease modifying therapy available for ALS. Using the statistical motor unit number est...
متن کاملProtocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]
BACKGROUND Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disorder characterised by loss of motor neurons leading to severe weakness and death from respiratory failure within 3-5 years. Riluzole prolongs survival in ALS. A published report has suggested a dramatic effect of lithium carbonate on survival. 44 patients were studied, with 16 randomly selected to take LiCO3...
متن کامل